Advertisement

Antipsychotics: Neurophysiological Properties (in Man)

  • J. Roubicek
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 55 / 1)

Abstract

Antipsychotics (neuroleptics) introduced the era of psychopharmacology and quite early on, as soon as favorable clinical activity had been ascertained, their neurophysiological properties were intensively explored. Compared to the well known EEG profiles of previously used psychoactive substances, e.g., barbiturates, opioids, stimulants, and psychodysleptics, the new antipsychotics proved to possess very clear-cut profiles.

Keywords

Schizophrenic Patient Dominant Frequency Normal Volunteer Psychoactive Drug Contingent Negative Variation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aghajanian, J., Bunney, B.: Dopaminergic neurons of the substantia nigra. J. Pharmacol. Exp. Ther.5 (Suppl. 1), 58 (1974)Google Scholar
  2. Bartholini, G.: Differential effect of neuroleptic drugs on dopamine turnover in the extrapyramidal and limbic system. J. Pharm. Pharmacol. 28, 429–433 (1976)PubMedCrossRefGoogle Scholar
  3. Berger, H.: Über das Electroenzephalogramm des Menschen. Arch. Psychiatr. Nervenkr. 87, 527–570 (1929)CrossRefGoogle Scholar
  4. Borenstein, P., Cujo, P., Chiva, M.: A propos de la classification des substances psychotropes selon leurs effects sur l’EEG. Ann. Med. Psychol. 2, 429–452 (1965)Google Scholar
  5. Brazier, M.: The application of computers to EEG. In: Computers in Biomedical Research Brazier, M. (ed.) Vol.1, pp. 2–9. New York: Academic Press 1965Google Scholar
  6. Carlsson, A.: Receptor-mediated control of dopamine synthesis. J. Pharmacol. (Suppl. 1), 5, 58 (1974)Google Scholar
  7. Christensen, A., Fjalland, B., Moller-Nielsen, T.: On the supersensitivity of dopamine receptors, induced by neuroleptics. Psychopharmacology 48, 1–6 (1976)PubMedCrossRefGoogle Scholar
  8. Ciganek, L.: Die EEG Lichtreizantwort der menschlichen Hirnrinde. S.A.V. Bratislava (1961)Google Scholar
  9. Curry, S.: Chlorpromazine: concentration in plasma, excretion in urine and duration effect. Proc. R. Soc. Med.64, 285–289 (1971)PubMedGoogle Scholar
  10. Domino, E.: Sites of action of some central nervous system depressants. Annu. Rev. Pharmacol., 215–268 (1962)Google Scholar
  11. Fink, M.: EEG and behavioral effects of psychopharmacologic agents. Neuropsychopharma-cology 7, 441–446 (1961)Google Scholar
  12. Fink, M.: EEG and Human Psychopharmacology. Annu. Rev. Pharmacol.9, 241–258 (1969)PubMedCrossRefGoogle Scholar
  13. Fink, M.: EEG profiles and bioavailability measures of psychoactive drugs. In: Modern Problems of Pharmacopsychiatry (Itil, T., ed.), Vol. VIII pp. 76–98. Basel: Karger 1974Google Scholar
  14. Fink, M.: Prediction of clinical activity of psychoactive drugs: Application of cerebral elec-trometry in phase I studies. In: Predictability in Psychopharmacology (Sudilowsky, A., Gershon, S., Beer, B., eds) New York; pp. 65–88. Raven Press 1975Google Scholar
  15. Guillemin, R., Ling, N., Burgus, R.: Endorphines, peptides d’origine hypothalamique et neuro-hypophysaire a activité morphinométique. Isolement et structure molèculaire d’α-endor-phine. Cr. hebd. Séanc. Acad. Sci. Paris, Sér. D, 282, 783–785 (1976)Google Scholar
  16. Itil, T.M., Keskiner, A., Fink, M.: Therapeutic studies in “therapy resistant” schizophrenic patients. Compr. Psychiatry, 7, 488–493 (1966)PubMedCrossRefGoogle Scholar
  17. Itil, T.M.: EEG and Pharmacopsychiatry. In: Clinical Pharmacology (Freyhan, F., ed.), pp. 163–194. Basel: Karger 1968Google Scholar
  18. Itil, T.M., Hsu, W., Saletu, B., Mednick, S.: Computer EEG and evoked potential investigations in children of high risk for schizophrenia. Am. J. Psychiatry 131, 892–900 (1974)PubMedGoogle Scholar
  19. Itill, T.M.,: Digital computer period analyzed EEG in psychiatry and psychopharmacology. In: Computerized EEG Analysis (Dolce, G., Künkel, H., eds.) pp. 289–308. Stuttgart: Fischer 1975Google Scholar
  20. Klik, J.: Experience with clozapine in psychiatric practice. Cesk. Psychiatr. 72, 197 (1976)Google Scholar
  21. Kline, N.S., Li, C.H., Lehmann, H.E., Lajtha, A., Laski, E., Cooper, T.: β-Endorphin-induced changes in schizophrenic and depressed patients. Arch. Gen. Psychiatry, in print (1977)Google Scholar
  22. Kogan, W., Nikolenko, N.: New drugs and the treatment of nervous and mental diseases. Report of Leningrad Bechterev Psychoneurol. Inst. 40 (1974)Google Scholar
  23. Kosterlitz, H., Hughes, J.: Peptides with morphine-like action in the brain. Br. J. Psychiatry 130, 298–304 (1977)PubMedCrossRefGoogle Scholar
  24. Matousek, M.: Automatic analysis in clinical EEG. Psychiatr. Research Inst., Prague (1967)Google Scholar
  25. Matousek, M., Roubicek, J., Vinar, O., Roth, J.: Klinische und electroencephalographische Kriterien der Auswahl der optimalen Medikation. Arzneim.-Forsch. 19, 438 (1969)Google Scholar
  26. Nahunek, K., Svestka, J., Misurec, J., Radova, A.: Experiences with clozapine. Cesk. Psychiatr. 71, 11 (1975)Google Scholar
  27. Roemer, D., Buescher, H.H., Hill, R.C., Pless, J., Bauer, W., Cardinaux, F., Closse, A., Hauser, D., Huguenin, R.: A synthetic enkephalin analogue with prolonged parenteral and oral analgesic activity. Nature 268, 547–549 (1977)PubMedCrossRefGoogle Scholar
  28. Roubicek, J.: Experimental psychoses. Cesk. Psychiatr., 57, 420–422 (1961)Google Scholar
  29. Roubicek, J., Major, I.: EEG profile and behavioral changes after a single dose of clozapine in normals and in schizophrenics. Biol. Psychiatry 12, 613–633 (1977)PubMedGoogle Scholar
  30. Roubicek, J., Srnec, J.: Experimental psychosis LSD. Cas. Lek. Cesk. 94, 189 (1955)PubMedGoogle Scholar
  31. Roubicek, J., Matejcek, M., Porsolt, R.: Computer analyzed EEG and behavioral changes after psychoactive drugs. Int. J. Neurol. 10, 33 (1975)PubMedGoogle Scholar
  32. Saletu, B.: Classification of psychotropic drugs based on human evoked potentials. In: Psychotropic Drugs and the Human EEG (Itil, T., ed). Basle: Karger 1974Google Scholar
  33. Saletu, B.: Psychopharmaka, Gehirntätigkeit und Schlaf. Basle: Karger 1976 Shagass, C.: Effects of psychotropic drugs in human evoked potentials. In: Psychotropic Drugs and the Human EEG (M, T., ed.), Vol. VIII, pp. 238–257. Basle: Karger 1974Google Scholar
  34. Shaw, J., O’Connor, P., Ongley, C.: The EEG as a measure of cerebral functional organization. Br. J. Psychiatry 130, 260–264 (1977)PubMedCrossRefGoogle Scholar
  35. Sulser, F., Stewart, R., Blumberg, T.: The limbic forebrain: The role of catecholamines in the action of antipsychotics. J. Pharmacol. Exp. Ther. 5, (Suppl. 1), 155 (1974)Google Scholar
  36. Walter-Grey, W., Cooper, R., Aldridge, V., McCallum, W., Winter, A.: Contingent negative variation. Nature 203, 380–384 (1964)CrossRefGoogle Scholar
  37. Wikler, A.: Clinical and electroencephalographic studies on the effects of mescaline, N-allylor-morphine and morphine in man. J. Nerv. Ment. Dis. 120, 157–175 (1954)PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1980

Authors and Affiliations

  • J. Roubicek

There are no affiliations available

Personalised recommendations